Company intelligence / Profile preview

Nanomega CryoAI

Wilmington, Delaware, USAcn.linkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nanomega CryoAI is an active biotech startup specializing in integrating cryogenic electron microscopy (cryoEM) with artificial intelligence to accelerate structure-based drug discovery. Their proprietary algorithms and high-throughput imaging platforms enable pharmaceutical companies and academic labs to visualize biomolecular structures at high resolution, supporting rapid validation of new drug designs. The company's clients include top pharma firms, AI-driven science enterprises, and leading universities worldwide. No direct clinical results as they do not develop therapeutics themselves.

Modalities: Small moleculeBiologicMonoclonal antibodyAntibody-drug conjugate
Industry: Drug Discovery Services

Partnerships

Partnerships with world-leading tech corporationsTop pharmaceutical companies

Beyond the preview

Go deeper on Nanomega CryoAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanomega CryoAI.

Explore the full profile